276 related articles for article (PubMed ID: 33149567)
1. Dual Bronchodilator in the Era of Triple Therapy.
Papaioannou AI; Loukides S; Bakakos P; Kosmas EN; Rovina N; Steiropoulos P; Fouka E; Hillas G; Patentalakis G; Kouvela M; Tzanakis N
Int J Chron Obstruct Pulmon Dis; 2020; 15():2695-2705. PubMed ID: 33149567
[TBL] [Abstract][Full Text] [Related]
2. Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.
Buhl R; Criée CP; Kardos P; Vogelmeier CF; Kostikas K; Lossi NS; Worth H
Int J Chron Obstruct Pulmon Dis; 2018; 13():2557-2568. PubMed ID: 30197512
[TBL] [Abstract][Full Text] [Related]
3. Triple Therapy in COPD: What We Know and What We Don't.
Calverley PMA; Magnussen H; Miravitlles M; Wedzicha JA
COPD; 2017 Dec; 14(6):648-662. PubMed ID: 29120273
[TBL] [Abstract][Full Text] [Related]
4. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
Wilkie M; Finch S; Schembri S
COPD; 2015; 12(5):582-90. PubMed ID: 25774769
[TBL] [Abstract][Full Text] [Related]
5. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
[TBL] [Abstract][Full Text] [Related]
6. Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety.
Suissa S; Dell'Aniello S; Ernst P
Int J Chron Obstruct Pulmon Dis; 2022; 17():1975-1986. PubMed ID: 36065315
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
8. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
9. [The stepwise approach of COPD therapy].
Watz H; Kirsten A; Greulich T
Dtsch Med Wochenschr; 2019 Jan; 144(1):15-20. PubMed ID: 30602182
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
11. When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment.
Cheng WC; Wu BR; Liao WC; Chen CY; Chen WC; Hsia TC; Tu CY; Chen CH; Hsu WH
Int J Chron Obstruct Pulmon Dis; 2020; 15():3375-3384. PubMed ID: 33376318
[TBL] [Abstract][Full Text] [Related]
12. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
[TBL] [Abstract][Full Text] [Related]
13. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
[TBL] [Abstract][Full Text] [Related]
14. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
15. Beyond Dual Bronchodilation - Triple Therapy, When and Why.
Cazzola M; Rogliani P; Laitano R; Calzetta L; Matera MG
Int J Chron Obstruct Pulmon Dis; 2022; 17():165-180. PubMed ID: 35068929
[TBL] [Abstract][Full Text] [Related]
16. Patterns and Trends in the Use of Medications for COPD Control in a Cohort of 9476 Colombian Patients, 2017-2019.
Machado-Duque ME; Gaviria-Mendoza A; Valladales-Restrepo LF; González-Rangel A; Laucho-Contreras ME; Machado-Alba JE
Int J Chron Obstruct Pulmon Dis; 2023; 18():1601-1610. PubMed ID: 37533774
[TBL] [Abstract][Full Text] [Related]
17. Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History.
Melani AS; Croce S; Fabbri G; Messina M; Bargagli E
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397432
[TBL] [Abstract][Full Text] [Related]
18. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
19. Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study.
Bloom CI; Douglas I; Usmani OS; Quint JK
Int J Chron Obstruct Pulmon Dis; 2020; 15():701-710. PubMed ID: 32308379
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
Kwak MS; Kim E; Jang EJ; Kim HJ; Lee CH
Int J Chron Obstruct Pulmon Dis; 2015; 10():2365-76. PubMed ID: 26604734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
